Hyun Suk Chong, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1558354100
Payments from drug & device makers
Across 172 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$750
- Lilly USA, LLC$645
- AbbVie$335
- Abbott$266
- Novo Nordisk$227
- Amgen$162
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$75020%
- Food & beverage$3,01780%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 3 | $750 |
| Lilly USA, LLC | 45 | $645 |
| AbbVie | 16 | $335 |
| Abbott | 13 | $266 |
| Novo Nordisk | 13 | $227 |
| Amgen | 10 | $162 |
| Boehringer Ingelheim | 8 | $145 |
| Sanofi-aventis U.S. LLC | 7 | $126 |
| Xeris Pharmaceuticals, Inc. | 6 | $116 |
| Insulet Corporation | 6 | $107 |
| Dexcom, Inc. | 8 | $101 |
| Cequr Corporation | 2 | $86 |
| Embecta Corp. | 4 | $86 |
| Corcept Therapeutics | 3 | $77 |
| Sequel Med Tech, LLC | 1 | $71 |
| Ascendis Pharma Endocrinology Inc | 2 | $58 |
| Mannkind Corporation | 4 | $51 |
| Amneal Pharmaceuticals LLC | 3 | $47 |
| Verity Pharmaceuticals Inc. | 2 | $41 |
| Lifescan, Inc. | 2 | $36 |
| Radius Health, Inc. | 2 | $35 |
| Ascensia Diabetes Care US Inc. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Cardinal Health 414 LLC | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| BD | 1 | $22 |
| Nevro Corp. | 1 | $17 |
| Bayer | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Gilead | 1 | $12 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,778 in reported general payments places this provider in the 50th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 182 | $227,929 |
| JardianceEmpagliflozin | 235 | $215,499 |
| TrulicityDulaglutide | 55 | $80,248 |
| TradjentaLinagliptin | 61 | $59,151 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $39,282 |
| JanuviaSitagliptin Phosphate | 50 | $37,041 |
| MounjaroTirzepatide | 22 | $36,602 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $34,934 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $34,080 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $29,914 |
| ProliaDenosumab | 16 | $28,159 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $25,094 |
| FarxigaDapagliflozin Propanediol | 17 | $22,617 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $17,935 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $16,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $145 | $274,650296 claims |
| Novo NordiskOzempic | $227 | $227,929182 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $645 | $124,479133 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $126 | $40,42770 claims |
| AmgenProlia | $162 | $28,15916 claims |
| AstraZenecaFarxiga | $11 | $22,61717 claims |
| AbbVieSynthroid | $335 | $9,978104 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $47 | $5,635565 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Phoenix
- Kevin YuenPhoenix$733K
- Joan BaileyPhoenix$316K
- Peter ReavenPhoenix$142K
- Sherman HarmanPhoenix$47K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- Richard ArakakiPhoenix$20K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.